Comparison Between 200 Mg QD and 100 Mg BID Oral Celecoxib in the Treatment of Knee or Hip Osteoarthritis

Overview

Journal Sci Rep

Specialty Science

Date 2015 May 28

PMID 26012738

Citations 7

Authors

Chao Zeng

Jie Wei

Hui Li

Tuo Yang

Shu-Guang Gao

Yu-Sheng Li

Yi-lin Xiong

Wen-Feng Xiao

Wei Luo

Tu-Bao Yang

Guang-Hua Lei

Affiliations

Soon will be listed here.

Abstract

This network meta-analysis aimed to investigate the effectiveness and safety of 100 mg BID and 200 mg QD oral celecoxib in the treatment of OA of the knee or hip. PubMed, Embase and Cochrane Library were searched through from inception to August 2014. Bayesian network meta-analysis was used to combine direct and indirect evidences on treatment effectiveness and safety. A total of 24 RCTs covering 11696 patients were included. For the comparison in between the two dosage regimens, 100 mg BID oral celecoxib exhibited a greater probability to be the preferred one either in terms of pain intensity or function at the last follow-up time point. For total gastrointestinal (GI) adverse effects (AEs), both of the two dosage regimens demonstrated a higher incidence compared to the placebo group. Further analyses of GI AEs revealed that only 200 mg QD was associated with a significantly higher risk of abdominal pain when compared with placebo. Furthermore, 100 mg BID showed a significantly lower incidence of skin AEs when compared with 200 mg QD and placebo. Maybe 100 mg BID should be considered as the preferred dosage regimen in the treatment of knee or hip OA.

Citing Articles

Use of Oral Celecoxib Preoperatively Reduces Risk of Delirium and Favors Functional Recovery in Elderly Patients with Femoral Neck Fracture: A Propensity Score-Matched Analysis.

Ju M, Han X, He L, Jiang J, Wang M, Lin W J Pain Res. 2025; 18:709-717.

PMID: 39975532 PMC: 11837742. DOI: 10.2147/JPR.S507116.

Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.

Martin Arias L, Martin Gonzalez A, Sanz Fadrique R, Salgueiro E, Sainz M Int J Clin Pharm. 2018; 40(4):928-935.

PMID: 30066292 DOI: 10.1007/s11096-018-0705-x.

Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy.

Zhou L, Zhou L, Su L, Cao S, Xie Y, Wang N J Neurosci. 2018; 38(13):3346-3357.

PMID: 29491011 PMC: 5884462. DOI: 10.1523/JNEUROSCI.3245-17.2018.

Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.

Zeng C, Wei J, Persson M, Sarmanova A, Doherty M, Xie D Br J Sports Med. 2018; 52(10):642-650.

PMID: 29436380 PMC: 5931249. DOI: 10.1136/bjsports-2017-098043.

Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study.

Trattler W, Hosseini K Ophthalmol Ther. 2017; 6(2):277-284.

PMID: 28819932 PMC: 5693819. DOI: 10.1007/s40123-017-0102-x.

References

Deeks J, Smith L, Bradley M . Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002; 325(7365):619. PMC: 126301. DOI: 10.1136/bmj.325.7365.619. View

Dias S, Welton N, Caldwell D, Ades A . Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010; 29(7-8):932-44. DOI: 10.1002/sim.3767. View

Hochberg M, Fort J, Svensson O, Hwang C, Sostek M . Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin. 2011; 27(6):1243-53. DOI: 10.1185/03007995.2011.580340. View

Bingham 3rd C, Sebba A, Rubin B, Ruoff G, Kremer J, Bird S . Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford). 2006; 46(3):496-507. DOI: 10.1093/rheumatology/kel296. View

DeLemos B, Xiang J, Benson C, Gana T, Pascual M, Rosanna R . Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2010; 18(3):216-26. DOI: 10.1097/MJT.0b013e3181cec307. View

Zhao S, McMillen J, Markenson J, Dedhiya S, Zhao W, Osterhaus J . Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy. 1999; 19(11):1269-78. DOI: 10.1592/phco.19.16.1269.30879. View

Paulson S, Hribar J, Liu N, Hajdu E, Bible Jr R, Piergies A . Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000; 28(3):308-14. View

Noyes Essex M, Zhang R, Berger M, Upadhyay S, Park P . Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Saf. 2013; 12(4):465-77. DOI: 10.1517/14740338.2013.780595. View

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

10.

Clegg D, Reda D, Harris C, Klein M, ODell J, Hooper M . Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354(8):795-808. DOI: 10.1056/NEJMoa052771. View

11.

Lumley T . Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21(16):2313-24. DOI: 10.1002/sim.1201. View

12.

White W, West C, Borer J, Gorelick P, LaVange L, Pan S . Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007; 99(1):91-8. DOI: 10.1016/j.amjcard.2006.07.069. View

13.

Antoniou K, Malamas M, Drosos A . Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin Pharmacother. 2007; 8(11):1719-32. DOI: 10.1517/14656566.8.11.1719. View

14.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

15.

Juni P, Reichenbach S, Dieppe P . Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol. 2006; 20(4):721-40. DOI: 10.1016/j.berh.2006.05.002. View

16.

Caldwell D, Ades A, Higgins J . Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521):897-900. PMC: 1255806. DOI: 10.1136/bmj.331.7521.897. View

17.

Conaghan P, Dickson J, Bolten W, Cevc G, Rother M . A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with.... Rheumatology (Oxford). 2013; 52(7):1303-12. DOI: 10.1093/rheumatology/ket133. View

18.

McAlindon T, Bannuru R, Sullivan M, Arden N, Berenbaum F, Bierma-Zeinstra S . OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22(3):363-88. DOI: 10.1016/j.joca.2014.01.003. View

19.

Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C . Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553):1302-8. PMC: 1473048. DOI: 10.1136/bmj.332.7553.1302. View

20.

Zeng C, Li H, Yang T, Deng Z, Yang Y, Zhang Y . Effectiveness of continuous and pulsed ultrasound for the management of knee osteoarthritis: a systematic review and network meta-analysis. Osteoarthritis Cartilage. 2014; 22(8):1090-9. DOI: 10.1016/j.joca.2014.06.028. View